Logo image of GENI

GENIUS SPORTS LTD (GENI) Stock Fundamental Analysis

NYSE:GENI - GG00BMF1JR16 - Common Stock

13.06 USD
+0.44 (+3.49%)
Last: 9/3/2025, 8:19:42 PM
13.03 USD
-0.03 (-0.23%)
After Hours: 9/3/2025, 8:19:42 PM
Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to GENI. GENI was compared to 134 industry peers in the Hotels, Restaurants & Leisure industry. No worries on liquidiy or solvency for GENI as it has an excellent financial health rating, but there are worries on the profitability. GENI is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year GENI has reported negative net income.
GENI had a positive operating cash flow in the past year.
GENI had negative earnings in each of the past 5 years.
In multiple years GENI reported negative operating cash flow during the last 5 years.
GENI Yearly Net Income VS EBIT VS OCF VS FCFGENI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 0 -200M -400M -600M

1.2 Ratios

With a Return On Assets value of -8.39%, GENI is not doing good in the industry: 82.84% of the companies in the same industry are doing better.
GENI's Return On Equity of -10.81% is in line compared to the rest of the industry. GENI outperforms 43.28% of its industry peers.
Industry RankSector Rank
ROA -8.39%
ROE -10.81%
ROIC N/A
ROA(3y)-14.16%
ROA(5y)-22.16%
ROE(3y)-19.14%
ROE(5y)-28.64%
ROIC(3y)N/A
ROIC(5y)N/A
GENI Yearly ROA, ROE, ROICGENI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

GENI has a Gross Margin of 23.57%. This is amonst the worse of the industry: GENI underperforms 82.09% of its industry peers.
The Profit Margin and Operating Margin are not available for GENI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 23.57%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GENI Yearly Profit, Operating, Gross MarginsGENI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 -50 -100 -150 -200

More info and screens

8

2. Health

2.1 Basic Checks

GENI does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for GENI has been increased compared to 1 year ago.
The debt/assets ratio for GENI has been reduced compared to a year ago.
GENI Yearly Shares OutstandingGENI Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 50M 100M 150M 200M
GENI Yearly Total Debt VS Total AssetsGENI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

An Altman-Z score of 8.31 indicates that GENI is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 8.31, GENI belongs to the top of the industry, outperforming 89.55% of the companies in the same industry.
GENI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 8.31
ROIC/WACCN/A
WACC9.25%
GENI Yearly LT Debt VS Equity VS FCFGENI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

GENI has a Current Ratio of 2.36. This indicates that GENI is financially healthy and has no problem in meeting its short term obligations.
GENI has a Current ratio of 2.36. This is amongst the best in the industry. GENI outperforms 89.55% of its industry peers.
A Quick Ratio of 2.36 indicates that GENI has no problem at all paying its short term obligations.
The Quick ratio of GENI (2.36) is better than 91.79% of its industry peers.
Industry RankSector Rank
Current Ratio 2.36
Quick Ratio 2.36
GENI Yearly Current Assets VS Current LiabilitesGENI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 18.42% over the past year.
GENI shows a strong growth in Revenue. In the last year, the Revenue has grown by 25.76%.
Measured over the past years, GENI shows a very strong growth in Revenue. The Revenue has been growing by 24.82% on average per year.
EPS 1Y (TTM)18.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-133.33%
Revenue 1Y (TTM)25.76%
Revenue growth 3Y24.82%
Revenue growth 5YN/A
Sales Q2Q%24.38%

3.2 Future

GENI is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 45.97% yearly.
GENI is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 16.61% yearly.
EPS Next Y51.27%
EPS Next 2Y57.23%
EPS Next 3Y45.97%
EPS Next 5YN/A
Revenue Next Year25.41%
Revenue Next 2Y21.09%
Revenue Next 3Y19.78%
Revenue Next 5Y16.61%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
GENI Yearly Revenue VS EstimatesGENI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 200M 400M 600M 800M 1B
GENI Yearly EPS VS EstimatesGENI Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 0 -1 -2 -3

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for GENI. In the last year negative earnings were reported.
With a Price/Forward Earnings ratio of 102.43, GENI can be considered very expensive at the moment.
66.42% of the companies in the same industry are cheaper than GENI, based on the Price/Forward Earnings ratio.
GENI's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 22.48.
Industry RankSector Rank
PE N/A
Fwd PE 102.43
GENI Price Earnings VS Forward Price EarningsGENI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GENI Per share dataGENI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates GENI does not grow enough to justify the current Price/Earnings ratio.
A more expensive valuation may be justified as GENI's earnings are expected to grow with 45.97% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y57.23%
EPS Next 3Y45.97%

More info and screens

0

5. Dividend

5.1 Amount

GENI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GENIUS SPORTS LTD

NYSE:GENI (9/3/2025, 8:19:42 PM)

After market: 13.03 -0.03 (-0.23%)

13.06

+0.44 (+3.49%)

Chartmill FA Rating
GICS SectorConsumer Discretionary
GICS IndustryGroupConsumer Services
GICS IndustryHotels, Restaurants & Leisure
Earnings (Last)08-06 2025-08-06/bmo
Earnings (Next)11-10 2025-11-10/bmo
Inst Owners92.2%
Inst Owner Change5.05%
Ins Owners8.64%
Ins Owner ChangeN/A
Market Cap3.30B
Analysts83.33
Price Target14.96 (14.55%)
Short Float %12.76%
Short Ratio4.83
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-581.75%
Min EPS beat(2)-1186.76%
Max EPS beat(2)23.27%
EPS beat(4)2
Avg EPS beat(4)-403.96%
Min EPS beat(4)-1186.76%
Max EPS beat(4)564.64%
EPS beat(8)2
Avg EPS beat(8)-245.45%
EPS beat(12)3
Avg EPS beat(12)-199.81%
EPS beat(16)4
Avg EPS beat(16)-161.92%
Revenue beat(2)0
Avg Revenue beat(2)-1.89%
Min Revenue beat(2)-2.01%
Max Revenue beat(2)-1.76%
Revenue beat(4)0
Avg Revenue beat(4)-1.67%
Min Revenue beat(4)-2.01%
Max Revenue beat(4)-0.92%
Revenue beat(8)1
Avg Revenue beat(8)-1.09%
Revenue beat(12)3
Avg Revenue beat(12)-0.04%
Revenue beat(16)7
Avg Revenue beat(16)1.52%
PT rev (1m)13.33%
PT rev (3m)21.21%
EPS NQ rev (1m)47.38%
EPS NQ rev (3m)-66.47%
EPS NY rev (1m)-386.79%
EPS NY rev (3m)-1425.8%
Revenue NQ rev (1m)7.69%
Revenue NQ rev (3m)11.23%
Revenue NY rev (1m)3.25%
Revenue NY rev (3m)3.69%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 102.43
P/S 5.92
P/FCF N/A
P/OCF 62
P/B 4.59
P/tB 11.89
EV/EBITDA N/A
EPS(TTM)-0.31
EYN/A
EPS(NY)0.13
Fwd EY0.98%
FCF(TTM)-0.08
FCFYN/A
OCF(TTM)0.21
OCFY1.61%
SpS2.21
BVpS2.85
TBVpS1.1
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -8.39%
ROE -10.81%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 23.57%
FCFM N/A
ROA(3y)-14.16%
ROA(5y)-22.16%
ROE(3y)-19.14%
ROE(5y)-28.64%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.6
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 117.79%
Cap/Sales 13.16%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.36
Quick Ratio 2.36
Altman-Z 8.31
F-Score6
WACC9.25%
ROIC/WACCN/A
Cap/Depr(3y)73.83%
Cap/Depr(5y)N/A
Cap/Sales(3y)12.81%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)18.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-133.33%
EPS Next Y51.27%
EPS Next 2Y57.23%
EPS Next 3Y45.97%
EPS Next 5YN/A
Revenue 1Y (TTM)25.76%
Revenue growth 3Y24.82%
Revenue growth 5YN/A
Sales Q2Q%24.38%
Revenue Next Year25.41%
Revenue Next 2Y21.09%
Revenue Next 3Y19.78%
Revenue Next 5Y16.61%
EBIT growth 1Y-30.56%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year363.54%
EBIT Next 3Y86.23%
EBIT Next 5Y54.25%
FCF growth 1Y71.18%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y322.19%
OCF growth 3YN/A
OCF growth 5YN/A